Dr. Axel Müller
Executive Consultant

Associate Partner at

Curriculum Vitae

As of 2020

Chairman of the Advisory Board of MIP Pharma Holding GmbH, Blieskastel/Germany

As of 2020

Member of the Supervisory Board at Mutares Management SE, München

As of 2018

Member of the Supervisory Board at Mutares SE & Co. KGaA, München (since 2019 Vice-Chairman of the Supervisory Board and Chairman of the Audit Comittee)

As of 2018

Associate Partner at Fidelio Healthcare Partners GmbH & Co. KG, Seefeld

as of 2014


2015 - 2018

Director/Senior Advisor at Arthur D. Little GmbH, Frankfurt

2010 - 2013

Executive Board Member for production and development of STADA Arzneimittel AG, Bad Vilbel

Collective Executive Board responsibility for the management of an MDAX-listed company with global reach with approx. 2 billion euros in revenue and over 8,000 employees worldwide.

Department responsibility for production, development (incl. regulatory affairs), procurement and supply chain, quality and portfolio management (incl. inlicensing).

Implementation of enterprise-wide “Build the Future” cost efficiency programme including establishment of new corporate governance in operations

Demonstrably highly successful: significant increase in the key financial figures of the STADA Group such as sales +25%, operating profit +34%, EBITDA +29%, net income +32% (H1/2010 vs. H1/2010) as well as share price > +40% (2013, August 6th vs. 2010, September 15th).

1993 - 2010

Exclusive (freelance) consultant of the Executive Board of STADA Arzneimittel AG on corporate strategy and project-related issues, e.g.:

  • Strategic positioning of the company in the individual markets and market segments (1993 – 2010)
  • Design of “STADA – Build the Future” cost efficiency programme (2009 – 2010)
  • Due diligence processes and contract negotiations in the areas of M&A, product acquisitions as well as inlicensing projects (1993 – 2010)
  • Monitoring of healthcare policy trends in Germany and the main EU markets and preparation of aligned position papers (1993 – 2010)

At the same time, gradual assumption of operations management responsibilities in the STADA Group (Vice President since 2005, Senior Vice President since 2008), including:

  • Head of brand business in Germany (STADA GmbH) with approx. 100 million euros revenue in the German OTC market (2009 – 2010)
  • Head of corporate communications including investor relations (2000 – 2010)
  • Country responsibility for Switzerland (1995 – 1999)
  • Project team leader for operational integration of an acquired product package (1995)
  • Head of generics business in Germany (STADApharm GmbH) (1995)
1985 - 1993

Various management positions at STADA Arzneimittel AG, including:

  • Head of Corporate development (1989 – 1993)
  • Head of business segment planning and marketing services (incl. market research and customer service centre) (1988 – 1993)
  • Strategic planning for generics (1987 – 1988)
  • OTC product management (1985 – 1987)
1980 - 1985

Research associate for the Chair of Pharmaceutical Technology at the Institute for Pharmaceutical Sciences at Johannes Gutenberg University of Mainz


Pharmacist licensure

1975 - 1980

Study of pharmaceutical sciences at Johannes Gutenberg University in Mainz


Born in Koblenz